VEEA INC. (NASDAQ: VEEA), an edge-computing and IoT hardware company, completed a 1-for-20 reverse stock split on August 28, 2026 — the maximum ratio the board was authorized to use. That left approximately 3.11 million shares outstanding, of which roughly 1.85 million trade freely after subtracting the 40.6% affiliate block controlled by CEO Allen Salmasi through NLabs Inc. and related entities.
Sitting behind that narrow float: approximately 7.65 million post-split shares of pending supply from warrants, convertible instruments, preferred stock, options, and at-market facilities. That is 414% of the current float — meaning every share trading today could theoretically be joined by more than four additional shares.
Three Live Dilution Pipes
The near-term structural risk is concentrated in three mechanisms that can deliver shares into the market right now, at or below prevailing prices:
1. White Lion convertible notes (~$1.11 million face). These convert at the lesser of $15.00 and 90% of the lowest volume-weighted average price over the prior ten trading days — meaning the conversion price floats downward with the stock. There is no disclosed floor. At recent levels, conversion would produce roughly 722,000 shares, equal to 39% of the entire float. A lower stock price does not reduce the threat; it increases it, because fewer dollars per share means more shares issued per dollar of principal.
2. Roth Capital ATM — a facility allowing the company to sell shares directly into the open market ($4.353 million capacity). At recent levels that capacity represents roughly 2.55 million shares, or 138% of the float. No per-sale filing is required. However, a regulatory cap called the "baby shelf" limitation — which restricts small issuers to selling one-third of their non-affiliate market value in any twelve-month window — has likely compressed usable capacity to roughly $1.05–$1.77 million as the company's non-affiliate market value has declined.
3. White Lion equity line of credit ($25 million notional, commitment period through June 2027). The company can issue shares to White Lion at prices as low as the day's lowest traded price. A 19.99% exchange cap — a Nasdaq rule limiting how many shares can be issued without shareholder approval — currently gates total usage at roughly 621,832 shares, about 34% of float. A shareholder vote scheduled by September 30, 2026 could lift that gate.
What Is Not a Near-Term Threat
The company's 3.83 million-share warrant book is entirely out of the money. The lowest exercise price is $6.20, and those warrants cannot even be exercised until January 1, 2027. Both preferred series — convertible into a combined 2.77 million common shares, or 150% of the float — also convert well above recent levels ($10.06 and $6.20). Voluntary conversion would destroy value for the holders.
This is the structural asymmetry that defines VEEA: the paper overhang from warrants and preferred is inert on the downside, but it hard-caps any upward move, because a higher stock price makes those instruments exercisable and simultaneously lifts the baby-shelf restriction, unlocking the full $75 million shelf registration — a filing that pre-authorizes future securities sales — which currently sits at roughly 14 times the company's market capitalization.
Issuance Cadence
The authorized share count was expressly not reduced proportionately with the reverse split, leaving roughly 27.5 million shares authorized against 3.11 million outstanding — an 8.8x headroom ratio that reloads the capacity consumed by the prior dilution cycle. Over the twelve months ending August 10, 2026, outstanding shares grew 24%. The company closed a financing or equity-settlement transaction in essentially every month of 2026.
One date to watch: $1.75 million of NLabs demand notes issued in July and August 2026 mature December 31, 2026. Every prior NLabs note has been settled in equity or convertible preferred rather than cash.